Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase
The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.


Pharmaceutical Technology


33. A.B. Csoka, G.I. Frost, and R. Stern, "The Six Hyaluronidase-like Genes in the Human and Mouse Genomes," Matrix Biol. 20 (8), 499–508 (2001).

34. Y. Lin et al., "A Hyaluronidase Activity of the Sperm Plasma Membrane Protein PH-20 Enables Sperm to Penetrate the Cumulus Cell Layer Surrounding the Egg," J. Cell. Biol. 125 (5), 1157–1163 (1994).

35. G.N. Cherr et al., "The PH-20 Protein in Cynomolgus Macaque Spermatozoa: Identification of Two Different Forms Exhibiting Hyaluronidase Activity," Dev. Biol. 175 (1), 142–153 (1996).

36. P. Gacesa, N.D. Civill, and R.A. Harrison, "PH-20 and Sperm Hyaluronidase: A Conceptual Conundrum in Mammalian Fertilization," Biochem. J. 303 (Pt. 1), 335–336 (1994).

37. G.I. Frost and R. Stern, "A Microtiter-based Assay for Hyaluronidase Activity not Requiring Specialized Reagents," Anal. Biochem. 251 (2), 263–269 (1997).

38. L.H. Bookbinder et al., "A Recombinant Human Enzyme for Enhanced Interstitial Transport of Therapeutics," J. Control Release 114 (2), 230–241 (2006).

39. H.D. Keiser and V.B. Hatcher, "The Effect of Contaminant Proteases in Testicular Hyaluronidase Preparations on the Immunologic Properties of Bovine Nasal Cartilage Proteoglycan," Connect Tissue Res. 6 (4), 229–233 (1979).

40. V.M. Doctor, H. Spence, and E.Y. Carroll, "Isolation and Properties of a New Anticoagulant Protein from Commercial Bovine Testicular Hyaluronidase," Thromb. Res. 30 (6), 565–571 (1983).

41. M. Hyuga, R. Kodama, and G. Eguchi, "Basic Fibroblast Growth Factor as One of the Essential Factors Regulating Lens Transdifferentiation of Pigmented Epithelial Cells," Int. J. Dev. Biol. 37 (2), 319–326 (1993).

42. J.C. Houck and C.M. Chang, "Permeability Factor Contaminating Hyaluronidase Preparations," Inflammation 3 (4), 447–451 (1979).

43. M. Oettl et al., "Comparative Characterization of Bovine Testicular Hyaluronidase and a Hyaluronate Lyase from Streptococcus agalactiae in Pharmaceutical Preparations," Eur. J. Pharm. 18 (3–4), 267–277 (2003).

44. M.F. Haller et al., "Escaping the Interstitial Matrix with Enzyme-Mediated Drug Delivery," Drug Delivery Technol. 5 (5), 40–45 (2005).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here